Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KP2021
- Development stage
- Unknown
- Lead developer
- K Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KP2021 is a small molecule drug candidate being developed by K Pharma, Inc. for the treatment of Frontotemporal Dementia (FTD). The compound was identified through K Pharma's proprietary iPSC-based drug discovery platform, which utilizes patient-derived induced pluripotent stem cells to model disease pathology and screen for therapeutic effects. As a repositioned drug, KP2021 is an existing compound being repurposed for FTD, a strategy intended to leverage established safety data to expedite clinical development timelines. The program is currently in the preparation phase for Phase 1/2 clinical trials, following the selection of the candidate compound.
Beyond the preview
Go deeper on KP2021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KP2021.